Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619446 | 0.90 | SMN1; SMN2 (0.44) | HPGDUSP2SMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL1702211 | 0.83 | USP2 (0.38) | HPGDUSP2SMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL662017 | 0.78 | USP30 (0.42) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL27426146 | 0.77 | USP2 (0.50) | HPGDUSP2SMN1; SMN2EPHX1TACR1 | |
| SCHEMBL2206945 | 0.76 | SMN1; SMN2 (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL24059733 | 0.76 | HPGD (0.59) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| Piperidine SCHEMBL7357986 | 0.76 | HPGD (0.59) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL31449542 | 0.75 | HPGD (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL31449872 | 0.75 | HPGD (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL31449824 | 0.75 | HPGD (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3515903-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | HPGD 1421/4885USP2 2688/4885SMN1; SMN2 3112/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | HPGD 1399/4885USP2 2627/4885SMN1; SMN2 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.